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49,9%, lipid–lowering 22,7% and Antidiabetics the 6,1% of the total annual follow 
up medication cost . For the patients were subjected to ICD initial implantation 
antiplatelet–anticoagulants represent 24,4 %, antiarrhythmic 2,2 %, cardiovascular 
44,2 %, lipid–lowering 25,0% and antidiabetics 4,1% of the total annual follow up 
medication cost. For the patients were subjected to ICD replacement antiplate-
let–anticoagulants represent the 28,7 %, antiarrhythmic the 7,7 %, Cardiovascular 
58,1 %, Lipid–lowering 5,5% and Antidiabetics 0,0% of the total annual follow up 
medication cost . ConClusions: The present study provides unique data regard-
ing the percentage of annual medication cost attributed to each kind of treatment 
of unselected patients subjected to CRMDs implantation in a real-world setting.
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objeCtives: To estimate the cost-effectiveness of strategies for treatment deep 
vein thrombosis (DVT), the primary objective was to compare of effects of catheter-
directed thrombolysis (CDT) and anticoagulation versus anticoagulation in the man-
agement of people with DVT of the lower limb. DVT occurs when a blood clot forms 
in a leg vein. The clot can break up and move to the lungs, leading to a potentially 
serious blockage in blood flow (pulmonary embolism). Because of the damage to 
the leg vein, post-thrombotic syndrome (PTS) may develop any time over the next 
couple of years. Methods: We used a Markov state transition decision model to 
evaluate the cost-effectiveness of treatment strategies using a societal perspective 
for costs, effectiveness-measured in incremental cost-effectiveness. Data sources 
included the English language literature using MEDLINE searches and bibliographies 
from selected articles. Results: Our study showed that CDT may have advan-
tages over standard anticoagulation treatment. CDT effectively dissolved the clot 
so that complete clot breakdown occurred more often with CDT than with standard 
anticoagulant therapy. CDT and anticoagulation with compression stockings was 
associated with an effectiveness of 21.67 QALYs and a lifetime cost of $48 442. The 
incremental cost-effectiveness ratio (ICER) was $14 728/QALY gained. CDT increases 
the patency of veins and reduces the incidence of PTS following DVT by 35%. Strict 
eligibility criteria are necessary to reduce the risk of bleeding complications and this 
limits the applicability of this treatment. ConClusions: CDT and anticoagulation 
are highly cost-effective strategies for treatment patients with DVT and a low risk of 
bleeding. Use of strict eligibility criteria has improved the safety and acceptability 
of this treatment, with treatment directed by catheter in more extensive clots now 
the favoured method.
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objeCtives: To evaluate the economic value of dabigatran in the treatment of 
deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recur-
rent events in comparison with other reimbursed oral anticoagulants warfarin 
and rivaroxaban from a perspective of Mexican public institutions. Methods: A 
Markov disease model with one month cycles length was developed. A number 
of parameters were followed in the model within the lifetime horizon (mean 18.2 
years from diagnosis for Mexican patients), including efficacy and safety relevant 
events and treatment related costs. Main modelling outcome was life-years gained. 
Identical hypothetical cohorts of patients entered the model, following either 
acute index DVT or PE (500 simulations per treatment arm). Modelled efficacy 
endpoints (recurrent venous thromboembolic events, including DVT, fatal and 
non-fatal PE), safety endpoints (major and clinically relevant non-major bleeds) 
and treatment related adverse events were utilized from published results of head 
to head clinical trials or derived in network meta-analysis and indirect compari-
sons. Public institutional direct medical costs (2014 purchases and price tabulators) 
where retrieved to adopt the national health system perspective. Results: Mean 
life-years saved for dabigatran, warfarin and rivaroxaban were 4.478, 4.475 and 
4.476 respectively. The highest cost of treatment was reported by rivaroxaban with 
7,959.15 USD, followed by warfarin (7,923.31 USD) and dabigatran (7,748.46 USD). 
ICER showed dabigatran is a dominant alternative versus both rivaroxaban and 
warfarin. Results were robust to changes in discount rates. Dabigatran remained 
as a dominant alternative versus rivaroxaban and as a cost-effective one ver-
sus warfarin, in a price sensitivity analysis. ConClusions: From a perspective 
of Mexican public institutions, the treatment with dabigatran resulted to be a 
cost-saving alternative that could potentially increase life-years gained without 
increasing health care spends.
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objeCtives: Atrial fibrillation (AF) is the most common cardiac rhythm disorder; it 
increases stroke risk 5 to 6 times. Prevalence in Colombia has been estimated in 3.6% 
in population age 60 or over (some 180 000 potential patients). The aim of this study 
was to estimate cost-effectiveness of dabigatran 110 mg and 150 mg BID as a therapy 
for non valvular AF in Colombian population. Methods: From a third-party payer 
perspective (Colombian health system) we used a three-month cycle Markov model 
with six health states (and death): non-disabling stroke, disabling stroke, acute myo-
cardial infarction and pulmonary embolism; two additional events were transient 
states: minor and mayor bleeding. Transition probabilities and proportion of events 
without CVEs for up to 3 years post-CVE, imposing a significant economic burden 
on U.S. commercial payers.
PCV59
thE inCrEMEntal Cost of rEoPErations for blEEDing EVEnts in 
CarDiaC anD VasCular rEConstruCtiVE surgEry
Gunnarsson C.1, Lim S.2, David G.3, Riebman J.B.2, Martin L.4, Kocharian R.2
1CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, 2Ethicon, Inc., Somerville, NJ, 
USA, 3The Wharton School, University of Pennsylvania, Philadelphia, PA, USA, 4Johnson & 
Johnson Medical Products, Markham, ON, Canada
objeCtives: Previous studies estimate that up to 15% of patients who undergo 
cardiovascular surgery require reoperation due to bleeding. The objective of this 
study is to estimate the incremental cost to hospitals for reoperations where a 
bleeding event is the primary reason across cardiovascular reconstructive surger-
ies. Methods: The study identified patients age 18 years or older with a record in 
the Premier hospital database between January 1, 2010 to September 30, 2012 who 
underwent cardiovascular reconstructive surgery. An algorithm (clinician expert 
rules and Premier Chargemaster data) was developed to define a reoperation where 
a bleeding event is the primary reason. Patients were excluded from analysis if 
extracorporeal circulation was utilized during the reoperation. The final sample 
included 294,548 patients in seven procedure groups: CABG, valve repair/replace-
ment, AAA repair, AV access, endarterectomy, femoral-femoral/femoral-popliteal 
bypass, and other vascular. Multivariable modeling was performed to estimate the 
incremental effect on hospital costs for bleeding events that required reoperation. 
Regression models to control for age, gender, race, marital status, insurance type, 
and severity and mortality risk were performed for each category of cardiac and 
vascular reconstructive surgery. Results: Descriptive results indicated that aver-
age hospital visit costs with no reoperation ranged between $10,832 [SD $10,731] 
and $48,768 [$28,368] depending on the procedure. The incremental additional cost 
per visit associated with a reoperation surgery for bleeding is estimated as follows 
by procedure group: CABG $30,951[$1,431]; valve repair $27,037 [$2,124]; AAA repair 
$30,145 [$1,235]; AV access $11,996 [$1,073]; endarterectomy $18,645 [$512]; fem-fem/
fem-pop bypass $44,383 [$1,699], and other vascular $25,861 [$432]. ConClusions: 
The incremental cost of reoperations for bleeding events in cardiac and vascular 
reconstructive surgery varied between 63% and 179% depending on the procedure 
group, with the largest increase for femoral-femoral bypass procedures, CABG, AAA 
repair, and valve procedures respectively.
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objeCtives: The objective of this investigation was to compare the contrasting 
results of recent cost-effectiveness analyses of statins. Methods: A systematic 
review of the literature on statin cost-effectiveness was conducted as per Cochrane 
methodology. Results: The four studies that met inclusion criteria reported vari-
able conclusions about the cost-effectiveness of statin treatment, without a clear 
unanimity as to whether statins are cost-effective for primary prevention. All stud-
ies analyzed health care costs from the health care system perspective – inclusive of 
and limited to all direct medical costs to all payers resulting from the statin therapy. 
The time horizon varied from as 5 years to lifetime. Annual drug prices ranged 
from $770 to over $1,500 in 2006 dollars. The studies reported varying assessments 
of the cost-effectiveness of statins. Costs ranged from $590,000 to $3 to extend 
life by one year. Recently published studies found statin therapy more likely to be 
cost-effective. However, when each study’s assumptions about statin costs were 
accounted, a substantial agreement among the authors was observed. Studies 
which assumed statins to be more costly found them to be less cost-effective, and 
vice-versa. Moreover, treatment of the lower risk groups appeared cost-effective as 
statins became cheaper. The studies were appraised using Philips and NICE checklist 
(qualitatively) and Quality of health economic studies (quantitatively). The studies 
were found to be of average quality. ConClusions: As the statins become generic, 
the chances of the patients at low risk for coronary disease may be treated cost-
effectively increases. It would be thus reasonable for clinicians to treat low-risk 
patients and statin therapy for a broader patient base, based on cost-effectiveness.
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objeCtives: To estimate the percentage of annual follow up medication cost attrib-
uted to each kind of treatment of unselected patients subjected to CRMDs implan-
tation in a real-world setting. Methods: During a period of one year in total 464 
(370 were subjected to PM implantation, 240 initial, 130 replacement and 94 to ICD 
implantation, 80 initial, 14 replacement) consecutive recipients were subjected to 
CRMD’s implantation and furthermore were recruited and followed up for 1 year. At 
six and twelve months after the procedure of implantation we record the medica-
tion use for each patient. Results: For the patients were subjected in PM initial 
implantation antiplatelet–anticoagulants represent 24,5%, antiarrhythmic 1,1,%, 
cardiovascular 47,8%, lipid–lowering 22,6% and antidiabetics 3,9% of the total annual 
follow up medication cost. For the patients were subjected to PM replacement anti-
platelet–anticoagulants represent 19,6%%, antiarrhythmic 1,7%, cardiovascular 
